NASDAQ:IOVA

Iovance Biotherapeutics Stock Forecast, Price & News

$47.55

-0.10 (-0.21 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$47.03

Now: $47.55▼

$48.86

50-Day Range

$43.11

MA: $48.42▼

$52.03

52-Week Range

$18.70

Now: $47.55▼

$54.21

Volume1.08 million shs

Average Volume1.28 million shs

Market Capitalization$6.97 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.94

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

MarketRank^™

Overall MarketRank^™

1.46 out of 5 stars

Medical Sector

479th out of 1,923 stocks

Biological Products, Except Diagnostic Industry

61st out of 177 stocks

2.4 Analyst's Opinion

Consensus Rating
Iovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.10, Iovance Biotherapeutics has a forecasted upside of 5.4% from its current price of $47.55.
Amount of Analyst Coverage
Iovance Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.2 Community Rank

Outperform Votes
Iovance Biotherapeutics has received 495 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Iovance Biotherapeutics has received 280 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Iovance Biotherapeutics has received 63.87% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote “Outperform” if you believe IOVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Iovance Biotherapeutics does not currently pay a dividend.
Dividend Growth
Iovance Biotherapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.90% of the stock of Iovance Biotherapeutics is held by insiders.
Percentage Held by Institutions
94.56% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Iovance Biotherapeutics are expected to decrease in the coming year, from ($1.85) to ($2.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iovance Biotherapeutics is -24.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iovance Biotherapeutics is -24.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Iovance Biotherapeutics has a P/B Ratio of 20.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:IOVA

Previous Symbol

CUSIPN/A

CIK1425205

Webwww.iovance.com

Phone650-260-7120

Employees148

Debt

Debt-to-Equity RatioN/A

Current Ratio11.24

Quick Ratio11.24

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.37 per share

Price / Book20.06

Profitability

EPS (Most Recent Fiscal Year)($1.59)

Net Income$-197,560,000.00

Net MarginsN/A

Return on Equity-50.64%

Return on Assets-45.64%

Miscellaneous

Outstanding Shares146,687,000

Market Cap$6.97 billion

Next Earnings Date2/23/2021 (Estimated)

OptionableOptionable

$47.55

-0.10 (-0.21 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

How has Iovance Biotherapeutics' stock been impacted by Coronavirus?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IOVA stock has increased by 60.8% and is now trading at $47.55.
View which stocks have been most impacted by COVID-19.

Is Iovance Biotherapeutics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Iovance Biotherapeutics?

Wall Street analysts have given Iovance Biotherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Iovance Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Iovance Biotherapeutics' CEO?

1,448 employees have rated Iovance Biotherapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Iovance Biotherapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Iovance Biotherapeutics.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) posted its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.06.
View Iovance Biotherapeutics' earnings history.

What price target have analysts set for IOVA?

11 brokerages have issued 12 month price targets for Iovance Biotherapeutics' stock. Their forecasts range from $35.00 to $65.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $50.10 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Iovance Biotherapeutics' key competitors?

Some companies that are related to Iovance Biotherapeutics include BioNTech (BNTX), Novozymes A/S (NVZMY), argenx (ARGX), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Fate Therapeutics (FATE), Novavax (NVAX), Acceleron Pharma (XLRN) and Kodiak Sciences (KOD).
View all of IOVA's competitors.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:

Dr. Maria Fardis M.B.A., Ph.D., MBA, CEO, Pres & Director (Age 52, Pay $1.2M)
Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel & Corp. Sec. (Age 46, Pay $571.2k)
Dr. Friedrich Graf Finckenstein M.D., Chief Medical Officer (Age 53, Pay $458.51k)
Mr. Jean-Marc Bellemin M.B.A., Chief Financial Officer (Age 48)
Ms. Sara Pellegrino, VP of Investor Relations & PR
Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 60)
Dr. Elma S. Hawkins, Advisor to the Board (Age 63)

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.40%), Rhenman & Partners Asset Management AB (0.22%), Peregrine Capital Management LLC (0.18%), First Midwest Bank Trust Division (0.01%), Vigilare Wealth Management (0.00%) and XR Securities LLC (0.00%).
View institutional ownership trends for Iovance Biotherapeutics.

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Candriam Luxembourg S.C.A., First Midwest Bank Trust Division, Rhenman & Partners Asset Management AB, Vigilare Wealth Management, and Pacer Advisors Inc..
View insider buying and selling activity for Iovance Biotherapeutics or view top insider-selling stocks.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was purchased by a variety of institutional investors in the last quarter, including XR Securities LLC.
View insider buying and selling activity for Iovance Biotherapeutics or or view top insider-buying stocks.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $47.55.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $6.97 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 148 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here